Daclatasvir (DCV) is a pangenotypic inhibitor of the HCV NS5A replication complex approved in Japan and Europe for combination treatment of HCV. AI444-063 was an open-label, two-stage, adaptive study assessing DCV pharmacokinetics and safety in HCV-uninfected subjects with renal impairment.
Methods
Stage 1 included 12 subjects with end-stage renal disease (ESRD) on dialysis and 12 healthy controls (creatinine clearance [CLcr]≥90 ml/min, Cockcroft-Gault) matched by sex, age and weight. All participants received a single DCV 60-mg dose on day 1. DCV plasma levels were measured through day 4. Prespecified criteria for study expansion (ESRD versus control area under the curve extrapolated to infinite time [AUC] geometric mean ratio [GMR] upper 90% CI>1.5) were met; therefore, 12 subjects with moderate or severe renal impairment (estimated glomerular filtration rate, 30–59 and 15–29 ml/min/1.73m2, respectively) were included in stage 2.
Results
All 36 participants (30 male, mean age 54 years) completed the study. DCV AUC∞was higher in ESRD subjects versus controls (GMR 1.264, 90% CI 0.989, 1.616). Compared with normal CLcr (90 ml/min), GMR and 90% CI for unbound DCV AUC∞at CLcr 60, 30 and 15 ml/min were 1.18 (1.07, 1.30), 1.39 (1.14, 1.70) and 1.51 (1.18, 1.94), respectively. DCV was generally well tolerated in subjects with normal renal function, ESRD, or moderate or severe renal impairment.
Conclusions
Observed DCV exposure increases were within the normal range of variability and were not associated with an elevated risk of adverse events. DCV can be administered in subjects with renal impairment, including ESRD, without dose modification. ClinicalTrials.gov NCT01830205.
References
1.
GaoM., NettlesR.E., BelemaM.Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.Nature2010; 465: 96–100.
2.
NettlesR.E., GaoM., BifanoM.Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.Hepatology2011; 54: 1956–1965.
3.
BifanoM., SevinskyH., StonierM., JiangH., BertzR.J.Daclatasvir, an HCV NS5A replication complex inhibitor, has minimal effect on pharmacokinetics of midazolam, a sensitive probe for cytochrome P450 3A4.8th International Workshop on Clinical Pharmacology of Hepatitis Therapy. 26–27 June 2013, Cambridge, MA, USA. Oral presentation O_15.
4.
BifanoM., HwangC., OosterhuisB.Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.Antivir Ther2013; 18: 931–940.
5.
BifanoM., AdamczykR., HwangC., KandoussiH., MarionA., BertzR.J.An open-label investigation into drug– drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects.Clin Drug Investig2015; 35: 281–289.
6.
BifanoM., SevinskyH., HwangC.Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.Antivir Ther2014; 19: 511–519.
7.
BertzR.Bristol-Myers Squibb HCV full development portfolio overview (plenary presentation).14th International Workshop on Clinical Pharmacology of HIV Therapy. 22–24 April 2013, Amsterdam, the Netherlands.
8.
Daklinza (daclatasvir).Summary of product characteristics2014. Bristol-Myers Squibb Pharma EEIGUxbridge, United Kingdom.
9.
Sovaldi (sofosbuvir).Summary of product characteristics2014. Gilead Sciences International LtdCambridge, United Kingdom.
10.
YeungC.K., ShenD.D., ThummelK.E., HimmelfarbJ.Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.Kidney Int2014; 85: 522–528.
11.
DreisbachA.W., LertoraJ.J.The effect of chronic renal failure on drug metabolism and transport.Expert Opin Drug Metab Toxicol2008; 4: 1065–1074.
12.
MichaudJ., NolinT.D., NaudJ.Effect of hemodialysis on hepatic cytochrome P450 functional expression.J Pharmacol Sci2008; 108: 157–163.
13.
Food and Drug Administration.Guidance for industry: pharmacokinetics in patients with impaired renal function– study design, data analysis and impact on dosing and labeling. (Updated 10 March 2010. Accessed 4 December 2014.) Available from http://www.fda.gov/downloads/Drugs/Guidances/UCM204959.pdf.
14.
LeveyA.S., BoschJ.P., LewisJ.B., GreeneT., RogersN., RothD.A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.Ann Intern Med1999; 130: 461–470.
15.
National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease.Am J Kidney Dis2002; 39: S76–S110.
16.
CockcroftD.W., GaultM.H.Prediction of creatinine clearance from serum creatinine.Nephron1976; 16: 31–41.
17.
JiangH., ZengJ., KandoussiH.A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclatasvir) in human plasma and urine.J Chromatogr A2012; 1245: 117–121.
18.
DilettiE., HauschkeD., SteinijansV.W.Sample size determination for bioequivalence assessment by means of confidence intervals.Int J Clin Pharmacol Ther Toxicol1991; 29: 1–8.
19.
MichaudJ., DubeP., NaudJ.Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450.Br J Pharmacol2005; 144: 1067–1077.
20.
ChanP., LiH., BifanoM.Population pharmacokinetic analysis of daclatasvir in subjects with hepatitis C virus (HCV) infection.J Pharmacokinet Pharmacodyn2014; 41: S40.
21.
ChanP., TafoyaE., BifanoM.Exposure-response analyses of daclatasvir in patients with genotype 1 chronic HCV infection: dose selection for Phase 3 clinical trials.7th International Workshop on Clinical Pharmacology of Hepatitis Therapy. 27–28 June 2012, Cambridge, MA, USA. Oral presentation O_11.
